Ask AI
Addressing atopic dermatitis with IL13 inhibition
Evidence-Based Care in Atopic Dermatitis: IL-13 Inhibitors to Treat Moderate to Severe Disease

Released: June 25, 2025

Expiration: June 24, 2026

Activity

Progress
1
Course Completed

In this episode, Andrew F. Alexis, MD, MPH; Daniel C. Butler, MD; and Shawn G. Kwatra, MD, discuss IL-13 inhibition for treating patients with moderate to severe atopic dermatitis (AD), including:

  • The available biologic therapies that specifically target IL-13
  • Where these agents fall in the 2024 American Academy of Dermatology treatment algorithm
  • How these agents compare to other AD therapies like topical corticosteroids and oral JAK inhibitors
  • A detailed patient case to highlight take home points